# Incannex Healthcare Inc.: financial statements, quarterly

IXHL · Nasdaq · CIK 1873875 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/ixhl.md) · [Financials](/companies/ixhl/financials.md) · [Filings](/companies/ixhl/filings.md) · [Insiders](/companies/ixhl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ixhl/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q2 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [0.1](/filings/0001213900-24-098421.md) | [0.0](/filings/0001213900-25-013783.md) | [0.0 d](/filings/0001213900-25-043682.md) | [0.0 d](/filings/0001628280-26-063506.md) | not reported | not reported | not reported | not reported |
| Research and development | $m | [2.6](/filings/0001213900-24-098421.md) | [2.6](/filings/0001213900-25-013783.md) | [3.3](/filings/0001213900-25-043682.md) | [4.4 d](/filings/0001213900-25-092837.md) | [2.9](/filings/0001213900-25-110299.md) | [1.4](/filings/0001213900-26-015867.md) | [2.7](/filings/0001213900-26-057227.md) | [3.7 d](/filings/0001628280-26-063506.md) | [1.1](/filings/0001213900-25-110299.md) | [2.3](/filings/0001213900-26-015867.md) | [0.3](/filings/0001213900-26-057227.md) | [1.5 d](/filings/0001628280-26-063506.md) |
| Operating income | $m | [(4.9)](/filings/0001213900-24-098421.md) | [(8.0)](/filings/0001213900-25-013783.md) | [(7.4)](/filings/0001213900-25-043682.md) | [(9.7) d](/filings/0001213900-25-092837.md) | [(6.3)](/filings/0001213900-25-110299.md) | [(5.0)](/filings/0001213900-26-015867.md) | [(5.0)](/filings/0001213900-26-057227.md) | [(7.5) d](/filings/0001628280-26-063506.md) | [(6.8)](/filings/0001213900-25-110299.md) | [(7.0)](/filings/0001213900-26-015867.md) | [(4.0)](/filings/0001213900-26-057227.md) | [(5.2) d](/filings/0001628280-26-063506.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [(0.0)](/filings/0001213900-25-110299.md) | [(0.0)](/filings/0001213900-26-015867.md) | [0.1](/filings/0001213900-25-043682.md) | [0.0 d](/filings/0001628280-26-063506.md) | [(0.0)](/filings/0001213900-25-110299.md) | [(0.0)](/filings/0001213900-26-015867.md) | not reported | not reported |
| Net income | $m | [(0.7)](/filings/0001213900-24-098421.md) | [(5.2)](/filings/0001213900-25-013783.md) | [(6.0)](/filings/0001213900-25-043682.md) | [(6.5) d](/filings/0001213900-25-092837.md) | [(5.4)](/filings/0001213900-26-057227.md) | [(5.9)](/filings/0001213900-26-057227.md) | [(4.0)](/filings/0001213900-26-057227.md) | [(31.6) d](/filings/0001628280-26-063506.md) | [(6.4)](/filings/0001213900-26-057227.md) | [(6.5)](/filings/0001213900-26-057227.md) | [(3.9)](/filings/0001213900-26-057227.md) | [(2.5) d](/filings/0001628280-26-063506.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001213900-24-098421.md) | [(0.33)](/filings/0001213900-25-013783.md) | [(0.38)](/filings/0001213900-25-043682.md) | not reported | [(0.29)](/filings/0001213900-25-110299.md) | [(0.33)](/filings/0001213900-26-015867.md) | [(6.19)](/filings/0001213900-26-057227.md) | not reported | [(0.02)](/filings/0001213900-25-110299.md) | [(0.02)](/filings/0001213900-26-015867.md) | [(0.35)](/filings/0001213900-26-057227.md) | not reported |
| Basic EPS | $ per share | [(0.08)](/filings/0001213900-24-098421.md) | [(0.33)](/filings/0001213900-25-013783.md) | [(0.38)](/filings/0001213900-25-043682.md) | not reported | [(0.29)](/filings/0001213900-25-110299.md) | [(0.33)](/filings/0001213900-26-015867.md) | [(6.19)](/filings/0001213900-26-057227.md) | not reported | [(0.02)](/filings/0001213900-25-110299.md) | [(0.02)](/filings/0001213900-26-015867.md) | [(0.35)](/filings/0001213900-26-057227.md) | not reported |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | Q2 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [14.6](/filings/0001213900-24-013611.md) | [9.3](/filings/0001213900-24-043391.md) | [5.9](/filings/0001213900-25-092837.md) | [3.6](/filings/0001213900-24-098421.md) | [2.1](/filings/0001213900-25-013783.md) | [6.7](/filings/0001213900-25-043682.md) | [15.0](/filings/0001628280-26-063506.md) | [73.3](/filings/0001213900-25-110299.md) | [68.9](/filings/0001213900-26-015867.md) | [74.5](/filings/0001213900-26-057227.md) | [67.7](/filings/0001628280-26-063506.md) |
| Current assets | $m | not reported | [21.3](/filings/0001213900-24-013611.md) | [16.3](/filings/0001213900-24-043391.md) | [16.2](/filings/0001213900-25-092837.md) | [15.2](/filings/0001213900-24-098421.md) | [10.5](/filings/0001213900-25-013783.md) | [15.6](/filings/0001213900-25-043682.md) | [20.0](/filings/0001628280-26-063506.md) | [78.3](/filings/0001213900-25-110299.md) | [74.7](/filings/0001213900-26-015867.md) | [80.1](/filings/0001213900-26-057227.md) | [72.8](/filings/0001628280-26-063506.md) |
| Total assets | $m | not reported | [22.4](/filings/0001213900-24-013611.md) | [17.3](/filings/0001213900-24-043391.md) | [17.0](/filings/0001213900-25-092837.md) | [16.0](/filings/0001213900-24-098421.md) | [11.1](/filings/0001213900-25-013783.md) | [16.2](/filings/0001213900-25-043682.md) | [20.4](/filings/0001628280-26-063506.md) | [78.7](/filings/0001213900-25-110299.md) | [75.0](/filings/0001213900-26-015867.md) | [80.3](/filings/0001213900-26-057227.md) | [73.0](/filings/0001628280-26-063506.md) |
| Current liabilities | $m | not reported | [3.2](/filings/0001213900-24-013611.md) | [2.9](/filings/0001213900-24-043391.md) | [5.6](/filings/0001213900-25-092837.md) | [9.2](/filings/0001213900-24-098421.md) | [5.8](/filings/0001213900-25-013783.md) | [7.4](/filings/0001213900-25-043682.md) | [7.0](/filings/0001628280-26-063506.md) | [1.6](/filings/0001213900-25-110299.md) | [1.5](/filings/0001213900-26-015867.md) | [1.9](/filings/0001213900-26-057227.md) | [1.5](/filings/0001628280-26-063506.md) |
| Total liabilities | $m | not reported | [3.5](/filings/0001213900-24-013611.md) | [3.1](/filings/0001213900-24-043391.md) | [5.8](/filings/0001213900-25-092837.md) | [9.5](/filings/0001213900-24-098421.md) | [10.1](/filings/0001213900-25-013783.md) | [8.8](/filings/0001213900-25-043682.md) | [7.1](/filings/0001628280-26-063506.md) | [1.7](/filings/0001213900-25-110299.md) | [1.6](/filings/0001213900-26-015867.md) | [5.0](/filings/0001213900-26-057227.md) | [5.6](/filings/0001628280-26-063506.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [2.4](/filings/0001213900-25-013783.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [1.4](/filings/0001213900-25-013783.md) | [1.4](/filings/0001213900-25-043682.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [19.8](/filings/0001213900-25-013783.md) | [18.9](/filings/0001213900-25-013783.md) | [14.1](/filings/0001213900-24-043391.md) | [11.2](/filings/0001628280-26-063506.md) | [6.6](/filings/0001213900-26-057227.md) | [1.0](/filings/0001213900-26-057227.md) | [7.4](/filings/0001213900-26-057227.md) | [13.4](/filings/0001628280-26-063506.md) | [77.0](/filings/0001213900-26-057227.md) | [73.4](/filings/0001213900-26-057227.md) | [75.2](/filings/0001213900-26-057227.md) | [67.4](/filings/0001628280-26-063506.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q2 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,749)](/filings/0001213900-24-098421.md) | [(2,103) d](/filings/0001213900-25-013783.md) | [(4,351) d](/filings/0001213900-25-043682.md) | [(3,642) d](/filings/0001213900-25-092837.md) | [(2,245)](/filings/0001213900-25-110299.md) | [(5,627) d](/filings/0001213900-26-015867.md) | [(3,159) d](/filings/0001213900-26-057227.md) | [(1,482) d](/filings/0001628280-26-063506.md) | [(9,163)](/filings/0001213900-25-110299.md) | [(4,622) d](/filings/0001213900-26-015867.md) | [(2,456) d](/filings/0001213900-26-057227.md) | [3,374 d](/filings/0001628280-26-063506.md) |
| Capital expenditure | $k | [221](/filings/0001213900-24-098421.md) | [59.0 d](/filings/0001213900-25-013783.md) | [(6.0) d](/filings/0001213900-25-043682.md) | [3.0 d](/filings/0001213900-25-092837.md) | not reported | not reported | [0.0 d](/filings/0001213900-26-057227.md) | [0.0 d](/filings/0001628280-26-063506.md) | [2.0](/filings/0001213900-25-110299.md) | [4.0 d](/filings/0001213900-26-015867.md) | [5.0 d](/filings/0001213900-26-057227.md) | [(1.0) d](/filings/0001628280-26-063506.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1,138 d](/filings/0001213900-26-057227.md) | [7,080 d](/filings/0001628280-26-063506.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-03-31) | period not labelled (2023-09-30) | Q2 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [15.4](/filings/0001213900-24-013611.md) | [15.9](/filings/0001213900-24-043391.md) | [15.9](/filings/0001213900-24-098421.md) | [15.9](/filings/0001213900-25-013783.md) | [15.9](/filings/0001213900-25-043682.md) | [17.6](/filings/0001213900-25-110299.md) | [17.6](/filings/0001213900-26-015867.md) | [0.7](/filings/0001213900-26-057227.md) | [310](/filings/0001213900-25-110299.md) | [349](/filings/0001213900-26-015867.md) | [12.3](/filings/0001213900-26-057227.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,544,627 at 2026-09-24, from the cover of the [10-K filed 2026-09-25](/filings/0001628280-26-063506.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.